Abiopharma

Perrigo Announces Quarterly Dividend

Johnson & Johnson - Johnson & Johnsons RYBREVANTFASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour

Phunware Announces Key Appointments Following Successful HITEC Industry Conference; Expansion of AI Concierge Footprint

Veru to Participate in Fireside Chat at the Canaccord Genuitys 46th Annual Growth Investors Conference

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer

Full House Resorts Announces Second Quarter Earnings Release Date

Safe Pro Successfully Completes U.S. Army Project Convergence Capstone 6 Demonstrating AI-Powered Threat Detection and Mapping Capabilities Utilizing Drone-Based Imagery

Snail Games to Unveil 9 Yin Sutra: Immortal, a New Internally Developed AAA Title, at ChinaJoy 2026